View all news

    Janssen seeks expanded use of IMBRUVICA®▼ (ibrutinib) in two indications in Europe

    11/15/2018
    Download(opens in new window)PDF 316 KB

    Multimedia Files:

    View all news
    Questions? Please contact us:
    1-800-950-5089 investor-relations@its.jnj.com